Cardioprotection on Chemotherapy-Induced Cardiotoxicity
Launched by AIN SHAMS UNIVERSITY · Feb 25, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain medications can protect the heart from damage caused by chemotherapy. Chemotherapy can sometimes lead to a condition called cardiotoxicity, which harms the heart. The researchers are looking for ways to reduce this risk and keep patients’ hearts healthy while they undergo cancer treatment.
The trial is open to children and teenagers aged 2 to 18 years who are willing to participate. To join, a parent or guardian must agree to the study, and the young participants should be able to take oral medications. However, anyone who has an allergy to the cardioprotective medications cannot participate. If eligible, participants will receive the cardioprotective medications during their chemotherapy treatments and will be monitored for their heart health. This study aims to ensure that young cancer patients can receive the best possible care with minimal side effects on their hearts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
- • Ability to take oral medication.
- • Age 2-18 years at the time of diagnosis.
- Exclusion Criteria:
- • Documented allergy to cardioprotective medications
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Manal Hamed El-Hamamsy, Prof
Principal Investigator
Ain Shams University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported